Group 1: Company Overview and Strategy - Guoxin Health is focused on building a multi-level medical security system based on the "1+3+N" framework, addressing the needs for supplementary insurance and the pain points in commercial health insurance [2] - The company is implementing a "Digital Intelligence Innovation" strategy and has initiated the "AI in ALL" action to enhance its data processing capabilities and integrate AI technology across various medical fields [3] Group 2: Financial Performance - In 2024, the company achieved a revenue of approximately 356.9 million RMB, representing a year-on-year growth of 8.11%, while the net profit was approximately -11.5 million RMB, showing a reduction in losses by 85.72% [12] - The company’s revenue in 2024 compared to 2020 increased by about 150 million RMB, a growth rate of approximately 72% [8] Group 3: Market Position and Growth Potential - Guoxin Health has served over 70 regions under the DRG payment reform and maintains a leading market share in the DIP payment implementation across 40 regions [8] - The company is actively expanding its innovative services in health management, commercial insurance, and pharmaceutical innovation, which are expected to be new growth points [10] Group 4: Shareholder Engagement and Future Plans - As of March 31, 2025, the company had 70,199 shareholders, indicating a broad base of investor support [6] - The major shareholder plans to increase their stake in the company by investing between 100 million RMB and 200 million RMB within the next six months [13]

Group 1: Market Overview - As of March 31, 2025, there are 11 A-share listed companies in Qingdao West Coast New Area, with a total market capitalization of 197.499 billion yuan, accounting for 24% of the total market capitalization of A-share listed companies in the city [1] - The total assets of these 11 companies reached 201.772 billion yuan in the first quarter, representing a year-on-year growth of 7.8%, and accounting for 10% of the total assets of A-share listed companies in the city [2] - The total operating revenue of these companies was 33.661 billion yuan in the first quarter, with a year-on-year increase of 5.7%, making up 20.5% of the total operating revenue of A-share listed companies in the city [3] Group 2: Company Performance - In the first quarter, the 11 A-share listed companies achieved a net profit attributable to shareholders of 2.996 billion yuan, reflecting a year-on-year growth of 2%, and accounting for 21% of the total net profit of A-share listed companies in the city [5] - Seven companies in the area reported positive growth in net profit, with Qingdao Port and Sailun Tire each exceeding 1 billion yuan in net profit for the first quarter [5] - Notably, Sanxiang Technology reported a significant increase in net profit, with a year-on-year growth of over 320% [5] Group 3: Individual Company Highlights - Hisense Visual achieved an operating revenue of over 13 billion yuan in the first quarter, with a year-on-year growth of 5.3% [4] - Sailun Tire reported an operating revenue exceeding 8 billion yuan, with a year-on-year increase of 15.3% [4] - Huicheng Environmental Protection saw a substantial increase in total assets, with a year-on-year growth of 55% in the first quarter [2]

Group 1 - The company, Guo Xin Health Assurance Service Group Co., Ltd., will participate in the 2025 Qingdao Listed Companies Investor Online Reception Day and 2024 Annual Performance Briefing [1] - The event will be held online on May 12, 2025, from 15:00 to 17:00, allowing investors to engage with company executives [1] - Topics for discussion will include corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [1]

证券简称：国新健康 证券代码：000503 编号：2025-34 国新健康保障服务集团股份有限公司 关于参加 2025 年青岛辖区上市公司投资者网上集体接待日暨 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，国新健康保障服务集团股份有限公司 （以下简称"公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市 全景网络有限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待 日暨 2024 年度业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司高管将以在线交流形式就公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告！ 国新健康保障服务集团股份有限公司 董 事 会 二零二五年 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Viewpoints - The report highlights the acceleration of data value transformation, with high-quality datasets empowering AI development. The Digital China Summit emphasized the importance of high-quality datasets in driving AI advancements [4][5] - The establishment of various high-quality data collection projects across multiple cities indicates a growing focus on data-driven applications in sectors such as healthcare, transportation, education, and finance [5][6] - The report notes the launch of the first data asset securitization project in China, which marks a significant step in the marketization of data elements and provides a new financing channel for the digital economy [7][8] Summary by Relevant Sections Industry Basic Situation - The closing index is at 4675.66, with a 52-week high of 5440.49 and a low of 2805.53 [1] Relative Index Performance - The report provides a forecast of relative performance for the computer industry against the CSI 300 index, showing a potential increase of 24% to 46% from May 2024 to December 2025 [3] Key Companies and Investment Ratings - Notable companies in the industry include: - Sanwei Tiandi (Buy) with a closing price of 28.88 and a market cap of 2.23 billion - Shanghai Steel Union (Buy) with a closing price of 20.76 and a market cap of 6.62 billion - YunSai ZhiLian (Buy) with a closing price of 23.48 and a market cap of 32.11 billion - Shanda Diwei (Buy) with a closing price of 9.55 and a market cap of 3.82 billion - New Point Software (Buy) with a closing price of 33.00 and a market cap of 10.89 billion [10][12]

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the **AI in Healthcare** industry, highlighting the acceleration of AI medical orders and projects since the release of DeepSeek R1 in February 2024, marking a new growth phase for AI-enabled healthcare solutions [1][2]. Core Insights and Arguments 1. **Acceleration of AI Medical Orders**: - As of Q1 2025, over **100 hospitals** have deployed large models and related applications, with the release of WiNGPT2.8 based on DeepSeek [1]. - AI-related medical orders reached **488 million yuan** in 2024, representing a **106% year-over-year increase**. In Q1 2025, new AI medical contracts signed amounted to **139 million yuan**, showing a **211% year-over-year growth** [1]. - In 2024, there were **31 new IT orders** worth **580 million yuan**, and in Q1 2025, **8 new IT orders** were recorded, including AI large model deployments [1]. 2. **AI Medical Data Processing**: - By the end of 2024, the company's AI medical brain, YiduCore, processed over **5 billion medical records**, covering more than **1 billion patients** and serving **102 top hospitals** [1]. - The company provided AI digital solutions to over **80 hospitals** and produced over **3 million** pathology AI-assisted diagnostic reports, with "Di'an Smart Inspection" serving over **8,000 medical institutions** and **40,000 medical personnel** [1]. 3. **Trends and Policy Catalysts**: - The rapid iteration and innovation of domestic AI large models, such as DeepSeek, Alibaba's Qwen3, and Tencent's Turbo S, are crucial for driving AI applications across industries, potentially initiating a new IT construction cycle [1]. - The Ministry of Industry and Information Technology, along with six other departments, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" on April 24, emphasizing the need for AI empowerment in the pharmaceutical industry [2]. Additional Important Insights - The call suggests monitoring several companies involved in AI healthcare, including: - **Neusoft, Jiahe Meikang, Yidu Technology, Chuangye Huikang, Jiuyuan Yinhai, Guoxin Health, and Langma Information** for AI in healthcare [2]. - **AI in Pharmaceuticals**: Jingtai Holdings and Yingshi Intelligent (in IPO stage) [2]. - **AI in Health Management**: Meinian Health, Alibaba Health, JD Health, iFlytek Medical Technology, and Loxin Medical [2]. - **AI in Diagnostic Assistance**: Dian Diagnostics, Rundat Medical, Kingmed Diagnostics, BGI (medical group coverage), and Anbiping [2]. - **AI Digital Doctor Platforms**: Yimai Tong [2].

关于回购注销部分限制性股票暨通知债权人的公告 证券简称：国新健康 证券代码：000503 编号：2025-30 国新健康保障服务集团股份有限公司 公司本次回购注销的限制性股票共 125,800 股，预计公司总股本将由 981,312,532 股变更为 981,186,732 股，注册资本也将由 981,312,532 元变更为 981,186,732 元。 具体内容详见公司于 2025 年 2 月 21 日和 5 月 7 日在《中国证券报》《上海 证券报》《证券时报》及巨潮资讯网（网址：www.cninfo.com.cn）披露的相关公 告。 本次公司回购注销部分股份将导致公司注册资本减少，根据《中华人民共和 国公司法》等相关法律法规的规定，公司债权人有权自接到公司通知之日起 30 日内，未接到通知的自本公告披露之日起 45 日内，凭有效债权证明文件及凭证 向公司要求清偿债务或提供相应担保。债权人如逾期未向公司申报上述要求，不 会因此影响其债权的有效性，相关债务（义务）将由公司根据原债权文件的约定 继续履行。本次回购股份的注销将按法定程序实施。 债权人可采用信函或传真的方式申报，具体方式如下： 1.申报时间：2 ...

证券简称：国新健康 证券代码：000503 编号：2025-33 国新健康保障服务集团股份有限公司 关于公司董事会、监事会换届完成并聘任高级管理人员及其他人 员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）于2025年5月6 日召开2025年第一次临时股东大会，审议通过了《关于选举公司第十二届董事 会非独立董事的议案》《关于选举公司第十二届董事会独立董事的议案》《关 于选举公司第十二届监事会股东代表监事的议案》。同日公司召开的第十二届 董事会第一次会议，审议通过了选举董事长、选举董事会各专门委员会委员、 聘任高级管理人员及证券事务代表等议案；召开的第十二届监事会第一次会议 审议通过了《关于选举公司第十二届监事会主席的议案》。现将相关情况公告 如下： 一、第十二届董事会组成情况 （一）董事会组成 1、非独立董事：李永华先生（董事长）、袁洪泉先生、姜开宏先生、王东 兴先生、松敏女士、刘英杰先生； 2、独立董事：孙娜女士、白彦先生、孙洁女士。 公司第十二届董事会由上述9名董事组成，其中非独立董事6名，独立 ...

证券简称：国新健康 证券代码：000503 编号：2025-29 国新健康保障服务集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、本次股东大会未出现否决提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会采用现场和网络投票相结合的方式。 一、会议的召开情况 国新健康保障服务集团股份有限公司（以下简称"公司"）2025 年第一次 临时股东大会于 2025 年 5 月 6 日在北京市东城区沙滩后街 22 号院 2 号楼、3 号 楼公司会议室以现场和网络投票相结合的方式召开。本次会议由公司董事会召集， 由公司董事长李永华先生主持。 会议通知等相关文件已于 2025 年 4 月 15 日、2025 年 4 月 24 日在《中国证 券报》《上海证券报》《证券时报》以及巨潮资讯网（网址：www.cninfo.com.cn） 披露。会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 二、会议的出席情况 股东出席的总体情况： 通过现场和网络投票的股东 29 ...

北京观韬律师事务所 关于国新健康保障服务集团股份有限公司 2025年第一次临时股东大会的法律意见书 观意字 2025BJ001008 号 致：国新健康保障服务集团股份有限公司 北京观韬律师事务所（以下简称"本所"）受国新健康保障服务集团股份有 限公司（以下简称"公司"）委托，指派本所律师出席公司 2025 年第一次临时股 东大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》、《上市公司股东会规则》（以下简 称"《规则》"）以及公司现行有效的《公司章程》的有关规定，指派律师对公司 于 2025 年 5 月 6 日召开的公司 2025 年第一次临时股东大会（以下简称"本次股 东大会"）进行见证，出具本法律意见书。 为出具本法律意见书，本所律师查询了公司在信息披露媒体上刊登的相关公 告，核查了公司提供的有关本次股东大会的文件，听取了公司就有关事实的陈述 和说明，列席了本次股东大会。公司已经向本所律师提供了本所律师认为出具本 法律意见书所必需的、真实、准确、完整的原始书面材料、副本材料或者口头证 言，并无任何隐瞒、虚假、误导或重大遗漏之处；公司保证提 ...